1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Helix BioPharma Corp.

Helix BioPharma Corp.

HBP.TO
Helix BioPharma Corp.CA flagToronto Stock Exchange
1.43
CAD
+0.03
- -
109.22MMarket Cap
Helix BioPharma Corp.
HBP.TO
(Toronto Stock Exchange)

Recent

price

1.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.37
0.35
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.22
-0.87
-1.3
-0.11
-0.61
-0.56
-0.56
-0.55
-0.43
-0.35
-0.35
-0.29
-0.22
-0.16
-0.21
- -
-0.03
Basic EPS, GAAP
-1.08
-0.83
-1.16
-0.58
-0.54
-0.54
-0.52
-0.53
-0.38
-0.26
-0.42
-0.34
-0.22
-0.14
-0.12
- -
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-7.38
-7.6
-1.06
-1.25
-1.4
-1.49
-1.71
-1.89
-1.92
-1.97
-1.69
-1.77
-1.59
-1.28
-1.17
- -
-0.49
Book Value per Share
1.33
1.69
0.46
0.37
0.48
0.43
0.18
- -
-0.08
-0.15
0.12
-0.05
0.01
-0.02
- -
- -
-0.05
Tangible Book Value per Share
12
13
13
13
14
16
17
18
20
21
26
28
30
39
44
56
76
Basic Weighted Avg Shares
4
5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-314.73
-275.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-14
-11
-17
-2
-9
-9
-10
-10
-9
-8
-9
-8
-7
-6
-9
- -
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-326.32
-250.55
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
13
19
5
4
6
6
3
-1
-2
-4
3
- -
- -
-1
- -
- -
-4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
- -
- -
- -
- -
- -
LT Debt
16
22
6
5
7
7
3
- -
-2
-3
3
-1
- -
-1
- -
- -
15
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
76
76
Market Capitalization
119
139
151

Working Capital

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
Total Current Assets
1
- -
3
Cash, Cash Equivalents & STI
- -
- -
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
7
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.02
-0.04
- -
-0.21
2025
-0.03
-0.03
-0.03
- -
- -
2026
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Bionomics Limited (BNOEF)
TetraLogic Pharmaceuticals Corporation (TLOG)
CNBX Pharmaceuticals Inc. (CNBX)
Nuformix plc (NFX.L)
Green Cross Cell Corporation (031390.KQ)
Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ)
Business
Helix BioPharma Corp Helix BioPharma Corp. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in immuno-oncology for the prevention and treatment of hard-to-treat cancers, including solid tumors and hematological malignancies; its lead product candidate, L-DOS47 (Tumor Defense Breaker), is a first-in-class antibody-enzyme conjugate targeting CEACAM6-overexpressing tumors such as non-small cell lung cancer, designed to neutralize the acidic tumor microenvironment and enhance immune checkpoint inhibitors like pembrolizumab, with Phase Ib trials completed; additional pipeline assets include LEUMUNA, an oral immune checkpoint modulator for post-allogeneic stem cell transplant leukemia relapse with US FDA Orphan Drug Designation and patent protection to 2041, and GEMCEDA, an oral prodrug of gemcitabine offering near-intravenous bioavailability for advanced cancers with patent coverage to 2043; the company also advances three CEACAM6-specific antibody-drug conjugates in discovery. Founded in 1995 and headquartered at Bay Adelaide Centre – North Tower, 40 Temperance Street, Suite 2, Toronto, Ontario, Canada, Helix BioPharma Corp. operates primarily in Canada with international clinical development activities. Recent developments include entering an asset purchase agreement in November 2024 with Laevoroc Immunology AG to acquire oral immune checkpoint assets, revising acquisition agreements with Laevoroc Immunology AG and Laevoroc Chemotherapy AG in December 2024 to finalize share consideration ahead of financing, completing the acquisition of certain oncology assets from Laevoroc entities in May 2025, and signing a capital-raising agreement in May 2025 with Kerentech Consulting Ltd. to support a USD 13 million bridge financing round aimed at advancing L-DOS47 and other priorities through 2025 and beyond.